GlassScriptPhysician profile
Joyce Wong
NPI 1417925629
$3,450.90
in general payments reported to CMS, 2019-2025
27 companies · $1,214 in 2025
The $1,214 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2021: $34.53 · 2022: $182 · 2023: $769 · 2024: $855 · 2025: $1,214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,482 · Education: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,481.53 |
| Education | $355.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $629.53 | 2023-2025 | Vyloy, Padcev, Xtandi |
| Pfizer INC. | $283.94 | 2021-2025 | |
| Abbvie INC. | $257.44 | 2023-2025 | Venclexta |
| Jazz Pharmaceuticals INC. | $243.42 | 2024-2025 | |
| Genentech USA, INC. | $232.24 | 2022-2025 | Lunsumio, Columvi, Tecentriq |
| Janssen Biotech, INC. | $221.46 | 2022-2025 | Rybrevant, Carvykti, Tecvayli |
| Iovance Biotherapeutics, INC. | $200.00 | 2025 | Amtagvi |
| Genzyme Corporation | $152.72 | 2023-2024 | |
| Novocure INC. | $123.39 | 2024 | Optune |
| Mirati Therapeutics, INC. | $112.39 | 2023 | Krazati |
| Sobi, INC | $110.92 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $97.46 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $95.15 | 2019-2023 | |
| Beigene USA, INC. | $90.52 | 2024 | Brukinsa |
| Lilly USA, LLC | $86.87 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intrinsiq Specialty Solutions, INC. | $80.35 | 2025 | |
| Rigel Pharmaceuticals, INC. | $72.73 | 2022 | |
| Array Biopharma INC | $69.22 | 2019 | |
| Incyte Corporation | $61.07 | 2019-2025 | Zynyz, Monjuvi |
| Servier Pharmaceuticals LLC | $53.47 | 2024-2025 | |
| Seagen INC. | $52.87 | 2022-2023 | Tivdak |
| Eisai INC. | $28.48 | 2024-2025 | |
| Asd Specialty Healthcare, LLC | $25.75 | 2019 | |
| Gilead Sciences, INC. | $22.72 | 2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $18.66 | 2023 | Imbruvica |
| Sumitomo Pharma America, INC. | $14.42 | 2025 | Orgovyx |
| Tersera Therapeutics LLC | $13.71 | 2024 | Zoladex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.